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The American College of Cardiology is pleased to 
announce that nearly 7,000 abstracts of original con- 
tributions were submitted to the Program Committee 
of the 45th Annual Scientific Session. Space and 
time considerations this year allowed the selection ef 
1,75$. 
Each abstract was peer reviewed by a panel of 
graders; chosen abstracts are presented in either oral 
or pester format. 
The American College of Cardiology thanks the 
thousands of abstract participants ant[ the hundreds of 
category graders and chairs for their efforts. 
James L. Ritchie, MD, FACC 
Chair 
1996 Annual Scientific Session Program Committee 
W. Douglas Weaver, M]D, FACC 
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Orange County Convention Center, Hall E 
Presentation Hour: 6:30 p.m.-8:30 p.m. 
ACUTE MYOCARDIAL INFARCTION - THERAPY 
Megadose Bolus Heparin as Reperfuslon Therapy 
for Acute Myocardial Infarction: Results of the 
HEAP Pilot ~udy 
Froek W,A. Verheugt, Randall C. Marsh, Gerdt Veen, Jean G.F, Bronzwasr, 
Felix Zijlslra. North Colorado Med Ctr, Greeley, CO; Free Univetsi[y 
Hospital, Amsterdam; University Hospital, Nijmegen; Weezenlanden 
Hospital, Zwotle, The Netherlands 
Anglography after thrombolyals for acute myocardial Infarction (AMI) Shows 
better patency when adjunct intravenous (iv) hepadn is used. We wondered, 
if iv hsparin alone also induces reparfusion. 
In the HEAP (Hepadn in Early Patency) pilot study 50 patients (pts) with < 
6 hours (h) signs; (>_ 2 mrs ST t in _> 2 leeds) and symptoms of AMI received a 
single iv bolus of 300 U/kg bepadn, a dose usually given by cardiac surgeons 
pdor to cardiopulmonary bypass. Doses of bolus heparin gwan varied from 
10,000 to 40,000 U. Aspirin (160 mg chewed), but no thrembolytic agent was 
given. Palency was assessed by coronary angiography at 90 minutes (rain) 
after the hepadn bolus. 
In 28/50 (56%) pts TIMI flow 2-3 was seen at 90 rain: TIMI flow 3 in 18 
(36%) pts and TIMI flow 2 in 10 (20%) pts. Pts with < 2 h symptoms (n = 
24) had 67% TIMI flow 2-3 versus 46% in pts with >_ 2 h symptoms (p = 
0.09). Pts with TIMI flow 0-1 underwent direct angiopiasty. At 90 rain aFTT 
exceeded 120 sec in all pta. No significant bleeding was seen. Aspidn 80 mg 
dally was given, as was heparin (aPTT 2.0-2.5) for 48 h. Predischarge anglo 
showed TIMI flow 3 in 15118 (83%) pts. 
Thus, early therapy with high-dose front-loaded hepadn alone can Induce 
fu;! coronary reperfusirm in pts with AMI, especially in early (<2 h) pts. 
This simple, inexpensive and easily antagonizable AMI treatment seems 
to be an attractive altemative to regular thrombolysis, beth in-hospital and 
pro-hospital, and can also be given prior to direct PTCA. 
~ Failure to Improve Outcome in Suspected Acute 
Myocardial Infarction by Pre-Hospital 
Administration of Aspirin 
Robert Greenbaum, Martin Flahen'y, Keen I.an Chan, Dan Shanit. 
Cardiovascular Research Unit Edgwam General Hospital and The London 
Ambulance Acodent and Emergency Service, London, UK 
The I~1S-2 trial has shown that in-hospital treatment of suspected acute 
myocardial infarction (AMI) patients with aspidn is almost as effective as 
treatment with streptokinase in reducing 35 day mortality. We carded out a 
Wospective, randomised, non-blir¢l, controlled study of the effect of adminis- 
tration of a single oral dose of 300 mg aspirin to patients with suspected AMI 
prior to Iransportation to hospital on 35 day mortality. The study was carded 
out over an eighteen month paded by front line ambulance crews based at 
15 London Ambulance Stations. 1850 patients with suspected acute myocar- 
dial infarction aged over 30 years were screened for eligibility. 1652 were 
randomised by the ambulance crews. 999 were allocated to a sttatsgy of 
pre-hospital aspidn and 653 allocated to ~nttol (no aspidn). 980 (98%) of 
those allocated to the treatment group received the medication. At 35 days 
there were 91 deaths in the aspidn group (9.1%) compared with 56 (8.6%) in 
the control group, The absolute increased risk 0.5% (95% confidence inter- 
val -2.26% to 3.3%) was not significant. The majority of deaths were due to 
cardiac causes 77 (85%) in the aspirin group and 47 (84%) in control. There 
were no major side effects atfo'butable to pre-haspital aspidn. Dudng long 
term 24.-,38 months follow up, there were 248 deaths (24.8%) in the aspidn 
group and 163 (25%) in the control group. This 0.2% reduction in the risk 
of death (95% confidence intenral -4.4% to 4.1%) was not signif'canL We 
conclude that a policy of pre~ospitat administration of aspirin to patients wilh 
suspected acute myocardial infarotion is safe but does not improve outcome. 
• Early ePTT Measurements Are Nat • Surrogate for in 
Vivo Thrombin Inhibition Among Patients Receiving 
lnrombolyt ic  Therapy and Adjunctive 
Anticoagulatlon 
Richard G. Beeker, James Hebert, Thomas Hurley, Yuasheng Ma, 
Chdstopher P. Cannon, for the TIMI 5 Hemostasis and Thrombosis Study 
Group. Thrombosis Research Center, Univemity of Maasacl~usetts Mecrcal 
School, Worcester, MA 
The immediate goal of thrombolytic therapy is to rapidly establish and main- 
tain physiologic ¢oronaff adedal blood flow. Adjunctive anticoagulant therapy 
may be required to achieve optimal repeffusion; however, the target aPTT 
value has been difficult o establish. In TIMI 5, measures of thrombln ac- 
tivity (FPA) and thmmbin generation (FI.2) were ol~,ained sedally in 246 
patients receiving accelerated tPA and either hepafin or himd~n. FPA and 
FI.2 levels at 12 and 24 h did not correlate with aPTT at these time points 
in either hepadn or hirudin-treated patients. An aPTT > 90 see (commonly 
considered high-intensity anticeegulation), was not consistently associated 
with decreased thrombin activity or generation. In fact, lhe lowest combin~l 
FPA and F1.2 value was seen with a 12 h aPTT Of ~ 60 
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We conclude that early aPTT measurements do not reliably reflect hrombin 
inhibition following thrombelysls with tPA and adjunctive ant(coagulation. 
ACUTE MYOCARDIAL  INFARCTION/UNSTABLE 
ANGINA 
~ Cardiac Two-Year Mortal ib/Related to Initial Specific 
Post.Thrombolytic F low Grade 
Kann S. Coyne, Pamela L. Walker, Jonathan S, Ralnar, Yasmine C. Dreoui, 
Cynthia A. Fink, Conor F. Lundergan, Allan M. Ross. George Washington 
University, Washington, DC 
Large clinical myocardial infarction trials with Iong-tarm feflow-up generally 
report late all-cause mortality. In a two year follow-up study of the GUSTO-1 
Angiographio cohort, we sought to relate early (90 minute) post-MI coro- 
nap/patancy to 2-year sundval. Uniquely, however, we have specific cause 
of death (as determined by death certificate, autopsy report, or hospital 
summary) obtained for 92.9% of all patients who died between the index 
hospitalization and two years and who had a 90 minute TIMI flow grade 
assessment (n = 127). Cardiac causes were defined as acute myocardial in- 
farction, congestive heart failure, and sudden deatWanhythmia. Differences 
in cause are displayed according tO 90 minute TIMI flow grade status. 
All.Cause Cardiac Cause Non-Cardiac 
TIMI O, 1 54/347 (15.6%) 44 (12.7%) 10 (2.9%) 
TIMI 2 4PJ305 (13.8%) 34 (11.1%) 8 (2.6%) 
TIMI 3 31/394 (7.9%)* 17 (4.3%)* 14 (3.6°/.) 
°T3 vs. T0,1. 2, p < 0.001 
TIM) 3 flOW results in a 48"/0 reduction in all-cause 2-year mortality while a 
64% reduction is demonstrated with cardiac specific 2.year mortality. 
Conclusion: in post-MI patients, successful immediate treatment (TIMI 3 
flow) leads to dramatic decreases in Iong-tarm all.cause and cardiac deaths. 
All-cause mortality reduction due to an open vessel may underestimate the 
true treatment effect due to existence of non-cardiac deaths. 
~ Influence of  Age and on the Prior Infarction Clinical 
Characteristics o f  Patients With Nbn.Q-Wave 
Myocardial Infarction 
Avanindra Jaln, Robert A. O'Rourke, William E. Beden, for the VANQWISH 
Investigators. Univ. TX. Hlth. Sci. Cntr., San Antonio, TX 
VA Non-Q-Wave Infarction Strategies in-Hospital (VANQWISH) is a prospec- 
tive randomized study to compare conservative strategy (radionuclide van- 
tricutography and exercise thallium) vs invasive strategy (cardiac catheteri- 
zation) in patients with non-Q-wave myocardial infarction (MI), To determine 
whether elderly patients or those with pdor MI have clinical features associ- 
ated with high dsk for cardiac events, we assessed baseline findings in 751 
patients with non-Q-wave MI. 
Age # lots EF High Risk Ti ETT+ LM/3VCAD 
<70 574 50% 27% 24% 42% 
>70 177 48% 41% 28°/. 55% 
p value NS 0.02 NS 0.01 
Ejection fraction - El =. High risk thallium (Ti) - multlzone ischemia or thallium lung uptake. 
ETT+ = positive xercise treadmill test. LM = left main, CAD = coronary artery disease. 
Patient.'3 with a prior MI had a significantly higher incidence of therapy with as- 
pidn (67%), nitrates (53%), beta-blockers (36%), and calcium blockers (52%). 
Prior MI #pts EF High Risk TI ETT+ LM/3VCAD 
Yes 326 47% 35% 27% 60% 
No 425 55% 27% 23% 33% 
p value 0.04 0.09 NS 0.01 
Accordingly, both older non-Q-wave MI patients and those with a prior MI have 
clinical findings indicating an increased dsk for subsequent cardiac events. 
~ Prognostic Signif icance of  ST Segment Monitor ing 
Early After Myocardial  Infarction: GUSTO ECG 
Substudy 
Anatefy Langar, Mitchell W. Krucof, Peter Klootwijk, Chdstopher Granger, 
Maarten Simoons, Paul W. Armstrong. St. Michael's Hospital, Toronto, ON, 
Canada; Duke Universi~ Durham, NC 
The GUSTO ECG Substudy enrolled 1,071 lOtS to provide a non-invasive 
assessment of the speed and stability of reparfusion. We studied 783 pts in 
whom ST segment analysis (> 18 hrs) was feasible (no signifiCant difference 
in baseline charactedstica from 288 pts excluded because of technical fas- 
tots) with respect to 30 day and I year mortality. ST segment shift (ST+) was 
defined as _> 1 mm ST$ from a 24 hr average baseline, measured at J + 60 
me and lasting > 1 roin. STt was measured similarly, but was restricted to 
beyond first 6 hrs from throrobelysis to allow adequate and stable resolution 
of initial STt. 
There were 414 pts (53%) with ST+ (186 pte had only ST,I,) who did not 
differ significantly from 369 ST - pts with respect to baseline characteds- 
tics. No difference in ST shift was seen between four different hrembolytic 
regimens. 
30 Day Mortality 1 Year Mortality 
ST- (n = 369) 1,9% 5,2% 
ST+ (n: 414) 6.0% ° 9.'~,o* 
°p <0.001 vs ST- 
ST segment shift (as a continuous variable) was an independent prediCtor 
of mortality when added to GUSTO mortality model. 
Conclusion: Detection of ST segment shift (ST? and STJ.) is a non-invasive 
marker of poor prognosis and may be incorporated in the early risk stratifica- 
tion of pts requidng further and more aggressive management. Lack of ST 
shift identifies low dsk population for whom cady discharge might be feasible. 
ACUTE MYOCARDIAL  INFARCTION/UNSTABLE 
ANGINA-  LONG TERM OUTCOME 
i 901-- '~ Growth Hormone Attenuates LV Remodel ing and 
Improves Cardiac Function in Rats With Large 
Myocardial  Infarction 
Antonio Cittadini, Jess(ca D. Grossman, Sarah E. Katz, James P. Morgan, 
Pamela S. Douglas. Beth Israel Hospital, Harvard Med. Sc,, Boston, MA 
To evaluate whether early Growth Hormone (GH) treatment improves cardiac 
remodeling and function after myocardial infarction (MI), we studied 32 male 
rats with sham surgery (n = 10) or MI induced by left coronary ligation. The day 
after surgery, the infarcted rats were randomized to receive 3 wk treatment 
with GH 3 mg/kg/day (MI-GH, n = 11) or placebo (MI, n = 11). Transthoracic 
echocardiography, LV catheterization and histology were obtained at 3 wk. 
Data are mean 4- SEM. 
LVRIW EDD/BW FS +dP/dt EDP 
Sham 2.42 :b 0.1 2.4 ~- 0.1 44 4- 2 7900 4" 340 3 ± 0.2 
MI 4.68±0.3" &5 :E0.2* 194-3' 3000±120" 244-2" 
MI-GH 3.60 :l: 0.2 .t' 2.8 4- 0.1 ,,1" 28 4- 2 *t 5500 =l: 140 *T 10 ± 2"t" 
*p < 0.05 vs sham; tp < 0.05 vs MI; BW = body weight (g); EDD = end-dicstolic d{men- 
sion (ram); FS = fractionalshortenlng (%);+dP/dt (mmHg/s); EDP = end.dic~Iolicpressure 
(mmHg). 
Average infarct size was 48 4- 4% in MI-GH and 47 4- 3% in MI. Although 
the increase in LV mass post MI was attenuated by GH, significant cellular hy- 
pertrophy was demonstrated by morphometdc histology in the non-infarcted 
tissue; call diameter in MI-GH group was 9.6 4- 0.3 p.m compared to both MI 
and sham groups (7.7 4- 0.2 and 7.5 ± 0.2 p.m, respectively; both p 4- 0.05 
vs MI-GH), while percent of fibrosis remained unchanged. 
Conclusions: 1. Compared to sham, MI rats exhibited LV dilatation, reduced 
FS and +dP/dt, and increased LV to BW ratio and EDR 2, GH treatment re- 
suited in less LV cavity dilatation and LV/BW despite increased royocyte 
size, and in the improvement of all indexes of cardiac function, These data 
demonstrate that eady GH treatment after large MI dramatically attenu- 
ates LV pathologic remodeling and improves systolic and diastolic function. 
GH-induced hypertrophy of non-infarcted myocytas may contdbute to these 
beneficial effects. 
[ ~ l s  Smoking Really Protective In Acute MI? 
Richard Davies, Helen Johansen, Murray Kaiserman, Jean Rouleau, 
Pierre Savarcl, Bruce Sussex, Martin Gardner, Claude Lauzon, 
Robert Dupuis, Duncan Stewart, Marlo Talajic, Wayne Warn(ca, Kathy Fods, 
Etel Mikes for the CAMI Investigators, Bureau of Tobacx~ Control, Ottawa 
Background: Current smokers have been reported to have a better post-MI 
prognosis than non-smokers. Four of the six articles found that smoking was 
stiU significantly associated with better survival after adjusting for age and 
other risk factors. We address this in a sequential sedes of 3,821 MI patients 
aged < 76 admitted to eight Canadian hospitals between July 1, 1990 ane 
December 30, 1992. 
Methods: Logistic models were constructed using different strategies tc 
correct for age, gender, disease ssvedty indices and dsk factors. 
